Gastroesophageal Junction Carcinoma — Research

Gastroesophageal Junction Carcinoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-13	166	`("Gastroesophageal Junction Carcinoma"[tiab] OR "Esophagogastric Junction Carcinoma"[tiab])`	2026-09-13	pubmed
Last 5 years	2021-01-01 → 2026-12-31	61	`("Gastroesophageal Junction Carcinoma"[tiab] OR "Esophagogastric Junction Carcinoma"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-13	pubmed
Last 12 months	2025-09-13 → 2026-09-13	13	`("Gastroesophageal Junction Carcinoma"[tiab] OR "Esophagogastric Junction Carcinoma"[tiab]) AND (2025/09/13:2026/09/13[dp])`	2026-09-13	pubmed

Data updated 18 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (32)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 1–25 of 32 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
· Lancet · 2010 · PMID 20728210 · validated civic_curation pubmed
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
· Lancet Oncol · 2017 · PMID 28958504 · validated civic_curation pubmed
Cyclin E in human cancers.
· FASEB J · 1999 · PMID 10224221 · validated civic_curation pubmed
Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis.